Pionyr Immunotherapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
64
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$48M
Pionyr Immunotherapeutics General Information
Description
Developer of cancer immunotherapies designed to target the tumor microenvironment to improve the body's antitumor immunity. The company's immunotherapies improve the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity, enabling patients to combat cancer, particularly in combination with checkpoint inhibitors.
Contact Information
Website
www.pionyrtx.comCorporate Office
- 2 Tower Place
- Suite 800
- South San Francisco, CA 94080
- United States
Corporate Office
- 2 Tower Place
- Suite 800
- South San Francisco, CA 94080
- United States
Pionyr Immunotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 04-Aug-2023 | $48M | Completed | Clinical Trials - Phase 1 | ||
| 10. Secondary Transaction - Private | 01-Apr-2023 | Completed | Clinical Trials - Phase 1 | |||
| 9. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 8. Later Stage VC | 01-Jul-2020 | Completed | Clinical Trials - General | |||
| 7. Early Stage VC (Series B) | 28-Mar-2018 | Completed | Clinical Trials - General | |||
| 6. Early Stage VC (Series A1) | 04-Jan-2017 | Completed | Clinical Trials - General | |||
| 5. Accelerator/Incubator | 01-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 08-May-2015 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 2. Accelerator/Incubator | 01-Jan-2015 | Completed | Pre-Clinical Trials |
Pionyr Immunotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 2,094,892 | $0.000100 | $0.06 | $0.71 | $0.71 | 1x | $0.71 | 3.45% |
Pionyr Immunotherapeutics Comparisons
Industry
Financing
Details
Pionyr Immunotherapeutics Competitors (88)
One of Pionyr Immunotherapeutics’s 88 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| Priothera | Venture Capital-Backed | Dublin, Ireland | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| EvolveImmune Therapeutics | Venture Capital-Backed | Branford, CT |
Pionyr Immunotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pionyr Immunotherapeutics Patents
Pionyr Immunotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023147306-A2 | Biomarkers for predicting responsiveness to immune checkpoint inhibitor therapy | Inactive | 25-Jan-2022 | ||
| WO-2023147306-A3 | Biomarkers for predicting responsiveness to immune checkpoint inhibitor therapy | Inactive | 25-Jan-2022 | ||
| AU-2022396551-A1 | Fibrosis treatment with anti-trem2 antibodies | Inactive | 29-Nov-2021 | ||
| CA-3239339-A1 | Fibrosis treatment with anti-trem2 antibodies | Pending | 29-Nov-2021 | ||
| EP-4441097-A1 | Fibrosis treatment with anti-trem2 antibodies | Pending | 29-Nov-2021 | C07K16/2803 |
Pionyr Immunotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pionyr Immunotherapeutics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gilead | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | Minority | ||
| Mission Bay Capital | Venture Capital | Minority | ||
| Mission BioCapital | Venture Capital | Minority |
Pionyr Immunotherapeutics FAQs
-
When was Pionyr Immunotherapeutics founded?
Pionyr Immunotherapeutics was founded in 2015.
-
Where is Pionyr Immunotherapeutics headquartered?
Pionyr Immunotherapeutics is headquartered in South San Francisco, CA.
-
What is the size of Pionyr Immunotherapeutics?
Pionyr Immunotherapeutics has 64 total employees.
-
What industry is Pionyr Immunotherapeutics in?
Pionyr Immunotherapeutics’s primary industry is Drug Discovery.
-
Is Pionyr Immunotherapeutics a private or public company?
Pionyr Immunotherapeutics is a Private company.
-
What is the current valuation of Pionyr Immunotherapeutics?
The current valuation of Pionyr Immunotherapeutics is .
-
What is Pionyr Immunotherapeutics’s current revenue?
The current revenue for Pionyr Immunotherapeutics is .
-
How much funding has Pionyr Immunotherapeutics raised over time?
Pionyr Immunotherapeutics has raised $353M.
-
Who are Pionyr Immunotherapeutics’s investors?
Gilead, , Johnson & Johnson Innovation - JLABS, Mission Bay Capital, and Mission BioCapital are 5 of 19 investors who have invested in Pionyr Immunotherapeutics.
-
Who are Pionyr Immunotherapeutics’s competitors?
Marengo Therapeutics, Meditope Biosciences, Priothera, Kite Pharma, and EvolveImmune Therapeutics are some of the 88 competitors of Pionyr Immunotherapeutics.
-
When was Pionyr Immunotherapeutics acquired?
Pionyr Immunotherapeutics was acquired on 04-Aug-2023.
-
Who acquired Pionyr Immunotherapeutics?
Pionyr Immunotherapeutics was acquired by Ikena Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
